The share price of Alnylam and Bluebird at the top of the market shows that you only need small signs of efficacy, some good deals and a recovering biotech market, rather than commercialised drugs to have a crazy market cap. BigPharma don't usually jump in when a good drug is well advanced through clinical trials (unless your Gilead and pay $11b for one drug before it finishes PII). They jump in when they think they can make money. Hedge funds jump in and out when they think they can made money by manipulating the share price. We have plenty of them unfortunately.
Donman, continually posting on BLT's thread for so long after you have sold and adding to current shareholder's misery with such negativity and worst case scenarios doesn't do anyone any good. Life is too short to be a Troll. Just look at plastic over at SS. He hasn't been able to let it go for over 10 years.
BLT Price at posting:
9.5¢ Sentiment: Hold Disclosure: Held
